VectivBio announces the date of the extraordinary general meeting of shareholders


Enter Wall Street with StreetInsider Premium. Claim your one week free trial here.

BASEL, Switzerland, Oct. 12, 2022 (GLOBE NEWSWIRE) — VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering new transformational treatments for severe rare diseases, today released the date of the Extraordinary General Meeting, to be held on Friday, December 9, 2022 at 10:00 a.m. CEST / 4:00 a.m. EDT at the offices of VectivBio Holding AG at Aeschenvorstadt 36, 4051 Basel, Switzerland.

The only item on the agenda of the Extraordinary General Meeting will be the election of Wouter Joustra as a new member of the Board of Directors.

In view of the ongoing COVID-19 pandemic, and in accordance with Ordinance 3 of the Swiss Federal Council concerning measures to combat the coronavirus (COVID-19), the Extraordinary General Meeting will be held without the personal presence of the shareholders. . The shareholders are represented at the Extraordinary General Meeting exclusively by the independent proxy. For more information on the procedures for exercising rights and transmitting voting instructions to the independent proxy, shareholders can access the invitation to the Extraordinary General Meeting at

About VectivBio AG

VectivBio is a global clinical-stage biotechnology company focused on transforming and improving the lives of patients with serious rare diseases. The lead product candidate, apraglutide, is a next-generation long-acting synthetic GLP-2 analog being developed for a range of rare gastrointestinal diseases where GLP-2 may play a pivotal role in the treatment of disease pathophysiology, including short bowel syndrome with intestinal failure (SBS-IF) and acute graft versus host disease (aGVHD).

VectivBio is also advancing its modular small-molecule CoMET platform to treat a wide range of previously untreatable inherited metabolic diseases (IMDs). CoMET leverages innovative chemistry, based on a proprietary stabilized pantetheine backbone, to restore fundamental cellular metabolism in pediatric populations with IPD characterized by a deficit in energy metabolism caused by depletion of functional coenzyme A (” CoA”). Candidates in the CoMET platform are initially evaluated in methylmalonic acidemia (MMA), propionic acidemia (PA) and other organic acidemias.

Learn more about www.vectivbio.comand follow us on LinkedIn and Twitter.

Forward-looking statements:

Forward-looking statements are statements that are not historical facts. Words and phrases such as “expected”, “forward”, “will”, “could”, “could”, “stay”, “potential”, “prepare”, “planned”, “believe”, “plan” , “near future”, “belief”, “guidance” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding the timing of the Extraordinary General Meeting. These statements are subject to risks and uncertainties, many of which are difficult to predict and generally beyond VectivBio’s control, that could cause actual results to differ materially from those expressed, implied or projected by the forward-looking statements. These risks and uncertainties include, but are not limited to: the impacts of the ongoing COVID-19 pandemic and the risks and uncertainties identified in the “Risk Factors” section of VectivBio’s Annual Report on Form 20-F filed with of the Securities and Exchange Commission on April 7, 2022 and its other subsequent filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, VectivBio undertakes no obligation to update these statements to reflect events that occur or circumstances that exist after the date on which they were made.


patrick malloy
VectivBio SVP, Investor Relations and Strategic Communications
[email protected]


Comments are closed.